Please enable Javascript and disable ad blockers

Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Show me how to use this page

Sensorion SA Stock

Price

Target price

/ Stuttgart Stock Exchange WKN: A14SVV / Name: Sensorion SA / Stock / Biotechnology & Medical Research / Micro Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

JS chart by amCharts

From: to:

Zoom:

Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

The full analysis of the stock Sensorion SA is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Sensorion SA

sharewise wants to provide you with the best news and tools for Sensorion SA, so we directly link to the best financial data sources.

Financials

News

Broker

News

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting

Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting

Sensorion Announces Presentation by Pr. Natalie Loundon at the 2025 American Society of Pediatric Otolaryngology Annual Meeting

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025

Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 12, 2025

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025

Sensorion to Host a Symposium during ISIET’s International Conference on Inner Ear Therapies on April 26, 2025

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025

Sensorion Announces Webconference, in French, for its Retail Shareholders on April 7, 2025

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences

Sensorion Announces its Participation at the Van Lanschot Kempen Conference Life Sciences

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing

BusinessWire_EN

0

Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report

Sensorion Reports Full-Year 2024 Results, Provides Corporate Update and Announces Availability of Full-Year Report

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity

Regulatory News:

Sensorion (FR0012596468 - ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial

Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN

0

Sensorion Announces Its Participation in Several Investor Conferences to be Held in March

Sensorion Announces Its Participation in Several Investor Conferences to be Held in March

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing

BusinessWire_EN

0

Sensorion Announces Its Participation In Several Congresses To Be Held In March

Sensorion Announces Its Participation In Several Congresses To Be Held In March

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing

BusinessWire_EN

0

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss

BusinessWire_EN

0

Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Announces Completion of Enrollment of The First Cohort of The Audiogene Phase 1/2 Gene Therapy Clinical Trial

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

BusinessWire_EN

0